Moderna

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. 

CEO
Stéphane Bancel
CEOStéphane Bancel
Employees
4,700
Employees4,700
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2010
Founded2010
Employees
4,700
Employees4,700

MRNA Key Statistics

Market cap
19.83B
Market cap19.83B
Price-Earnings ratio
-6.87
Price-Earnings ratio-6.87
Dividend yield
Dividend yield
Average volume
10.95M
Average volume10.95M
High today
$54.02
High today$54.02
Low today
$48.68
Low today$48.68
Open price
$48.70
Open price$48.70
Volume
8.09M
Volume8.09M
52 Week high
$55.20
52 Week high$55.20
52 Week low
$22.28
52 Week low$22.28

Stock Snapshot

As of today, Moderna(MRNA) shares are valued at $50.74. The company's market cap stands at 19.83B, with a P/E ratio of -6.87.

On 2026-02-23, Moderna(MRNA) stock traded between a low of $48.68 and a high of $54.02. Shares are currently priced at $50.74, which is +4.2% above the low and -6.1% below the high.

Moderna(MRNA) shares are trading with a volume of 8.09M, against a daily average of 10.95M.

In the last year, Moderna(MRNA) shares hit a 52-week high of $55.20 and a 52-week low of $22.28.

In the last year, Moderna(MRNA) shares hit a 52-week high of $55.20 and a 52-week low of $22.28.

MRNA News

Benzinga 2h
Moderna Stock Is Trading Higher Today: What's Going On?

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Monday. Piper Sandler boosted its price target on the stock to $69 from $63 while reiterating an Overweig...

Moderna Stock Is Trading Higher Today: What's Going On?
The Motley Fool 5h
Here's Why I Wouldn't Touch Moderna With a 10‑Foot Pole Until Its Next Growth Engine Is Clear

Moderna made a fortune with COVID vaccines, but revenue has since declined. Moderna (MRNA +6.17%) became a household name during the coronavirus pandemic. Ther...

Here's Why I Wouldn't Touch Moderna With a 10‑Foot Pole Until Its Next Growth Engine Is Clear
TipRanks 8h
Moderna price target raised to $69 from $63 at Piper Sandler

Piper Sandler raised the firm’s price target on Moderna (MRNA) to $69 from $63 and keeps an Overweight rating on the shares. The firm forecasts total product sa...

Analyst ratings

70%

of 27 ratings
Buy
14.8%
Hold
70.4%
Sell
14.8%

More MRNA News

TipRanks 2d
Moderna Faces Default Risk as Ares Capital–Led Lenders Gain Power to Accelerate Debt and Seize Collateral

Moderna (MRNA) has disclosed a new risk, in the Debt & Financing category. Failure by Moderna to comply with covenants under its Ares Capital–led credit agreem...

TipRanks 2d
Moderna Stock Soars as Flu Reversal Ignites Hopes

Moderna ( (MRNA) ) has risen by 17.69%. Read on to learn why. President's Day Sale - 70% Off Unlock hedge fund-level data and powerful investing tools for smart...

The Motley Fool 2d
Billionaire Philippe Laffont Just Dumped CoreWeave and Opened a Position in a Stock That Soared Nearly 50% in January.

Laffont's new addition may represent an exciting recovery story. Billionaire Philippe Laffont is known for investing in technology winners. The founder of Coat...

Billionaire Philippe Laffont Just Dumped CoreWeave and Opened a Position in a Stock That Soared Nearly 50% in January.
TipRanks 3d
Moderna and Merck Advance mRNA Cancer Vaccine Trial in First-Line Lung Cancer: What Investors Should Watch

Moderna (MRNA) announced an update on their ongoing clinical study. The Phase 2 study “A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in...

Benzinga 3d
Moderna Faces Lawsuit From BioNTech Over Next-Generation COVID-19 Shot

BioNTech SE (NASDAQ:BNTX) has filed a patent infringement lawsuit against Moderna Inc. (NASDAQ:MRNA) , alleging that Moderna's next-generation COVID-19 vaccine,...

Moderna Faces Lawsuit From BioNTech Over Next-Generation COVID-19 Shot
Simply Wall St 4d
Moderna Valuation Check After Recent Share Price Surge And Pipeline Expectations

Advertisement Why Moderna (MRNA) is on investors’ radar today Moderna (MRNA) has drawn fresh attention after recent share price moves, with the stock showing...

Moderna Valuation Check After Recent Share Price Surge And Pipeline Expectations
TipRanks 4d
Moderna Downgraded to Sell as Flu Program Uncertainty and Regulatory Risks Outweigh Upside

Analyst Alec Stranahan from Bank of America Securities reiterated a Sell rating on Moderna and increased the price target to $31.00 from $27.00. President's Day...

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.